81 results on '"Tani, Shinya"'
Search Results
2. Albumin change predicts failure in ulcerative colitis treated with adalimumab
3. Comparison of fecal calprotectin levels and endoscopic scores for predicting relapse in patients with ulcerative colitis in remission
4. Both MLH1 deficiency and BRAFV600E mutation are a unique characteristic of colorectal medullary carcinoma: An observational study
5. Expectations for the Dual Therapy with Vonoprazan and Amoxicillin for the Eradication of H. pylori
6. A comparison of two types of contrast media used in endoscopic retrograde cholangiopancreatography: A retrospective study
7. Importance of eosinophilic infiltration of the colonic mucosa in ulcerative colitis patients who are refractory to maintenance therapy: A prospective, single-center study
8. Effect of disease duration on fecal biomarkers in ulcerative colitis: a prospective cohort study
9. Modified method of patency judgement using patency capsule prior to capsule endoscopy in clinical practice
10. Lymphocyte to monocyte ratio and serum albumin changes predict tacrolimus therapy outcomes in patients with ulcerative colitis
11. Predicting Ulcerative Colitis Relapse in Clinical Remission With Fecal Immunochemical Occult Blood Test or Prostaglandin E-Major Urinary Metabolite
12. Influence of daily versus alternate-day dosing of vonoprazan on intragastric pH, serum gastrin, and the antiplatelet function of clopidogrel
13. Importance of Eosinophilic Infiltration of the Colonic Mucosa in Ulcerative Colitis Patients who are Refractory to Maintenance Therapy
14. Lymphocyte-to-monocyte ratio is a short-term predictive marker of ulcerative colitis after induction of advanced therapy
15. Lymphocyte-to-Monocyte Ratio as a Marker for Endoscopic Activity in Ulcerative Colitis
16. Usefulness of patency capsule prior to small-bowel capsule endoscopy in clinical practice: Validity of the modified method of patency judgement
17. Real-World Efficacy and Safety Monitoring for Predicting Continuation of Tofacitinib Therapy in Patients with Ulcerative Colitis
18. Further research on the clinical relevance of the ulcerative colitis colonoscopic index of severity for predicting 5-year relapse
19. Comparison between Prostaglandin E-major urinary metabolite and C-reactive protein levels to reflect endoscopic scores in patients with ulcerative colitis
20. Usefulness of the capsule endoscopy Crohn's disease activity index in assessing the necessity of early additional treatment in patients with Crohn's disease in clinical remission
21. Therapeutic monitoring of adalimumab at non-trough levels in patients with inflammatory bowel disease
22. Prevalence of UL97 gene mutations and polymorphisms in cytomegalovirus infection in the colon associated with or without ulcerative colitis
23. Early serum albumin changes in patients with ulcerative colitis treated with tacrolimus will predict clinical outcome
24. C-reactive protein is superior to fecal biomarkers for evaluating colon-wide active inflammation in ulcerative colitis
25. Effects of pirenzepine on vonoprazan-induced gastric acid inhibition and hypergastrinemia
26. Sa171 INFLUENCE OF DAILY OR ALTERNATE-DAY DOSING OF VONOPRAZAN ON INTRAGASTRIC PH, SERUM GASTRIN, AND THE ANTIPLATELET EFFECT OF CLOPIDOGREL; ADDITIONAL REPORT.
27. Sa238 CLASSIFICATION OF AUTOIMMUNE GASTRITIS BASED ON THE STATUS OF POLYGLANDULAR AUTOIMMUNE SYNDROME
28. Serum N-terminal telopeptide of type I collagen as a biomarker for predicting bone density loss in patients with Crohn disease
29. Prevalence of UL97 gene mutations in cytomegalovirus reactivation in the colon associated with or without ulcerative colitis
30. Evaluation of the modified Crohn's disease activity index in patients with Crohn disease with enterostomy
31. Mesalazine granule formulation improves clinical data in Crohn's disease compared with tablet formulation
32. Tuberous sclerosis patient with neuroendocrine carcinoma of the esophagogastric junction: A case report
33. Prostaglandin E-Major Urinary Metabolite Predicts Relapse in Patients With Ulcerative Colitis in Clinical Remission
34. The first evidence for SLFN11 expression as an independent prognostic factor for patients with esophageal cancer after chemoradiotherapy
35. Prevalence of UL97 gene mutations in cytomegalovirus reactivation in the colon associated with or without ulcerative colitis
36. The first evidence for SLFN11 expression as an independent prognostic factor for patients with esophageal cancer after chemoradiotherapy
37. Therapeutic Monitoring of Adalimumab at Non-Trough Levels to Gauge Its Efficacy in Patients with Inflammatory Bowel Disease in Clinical Practice
38. Serum N-Terminal Telopeptide of Type I Collagen as a Biomarker for Predicting Bone Density Loss in Patients with Crohn Disease
39. Improvement in Ulcerative Colitis by Administration of Benralizumab for Comorbid Refractory Bronchial Asthma: A Novel Clinical Observation
40. Microsatellite frameshift variants in SGO1 of gastric cancer are not always associated with MSI status
41. Estimation of the degree of gastric mucosal atrophy based on serum pepsinogen levels after eradication of Helicobacter pylori
42. The effect of early trough level of infliximab on subsequent disease course in patients with Crohn disease
43. The First Evidence for SLFN11 Expression As An Independent Prognostic Factor for Patients with Esophageal Cancer After Chemoradiotherapy
44. DNA mismatch repair is not disrupted in stage 0 colorectal cancer resected using endoscopic submucosal dissection
45. Effect of ulcerative colitis duration on the usefulness of immunochemical fecal occult blood test result as a disease activity biomarker
46. Photodynamic Therapy Using Talaporfin Sodium for Local Failure after Chemoradiotherapy or Radiotherapy for Esophageal Cancer: A Single Center Experience
47. Highly Bioavailable Curcumin Derivative Ameliorates Crohn’s Disease Symptoms: A Randomized, Double-Blind, Multicenter Study
48. A Case of Familial Mediterranean Fever Mimicking Acute Cholangitis
49. Sa1343 CLASSIFICATION OF AUTOIMMUNE GASTRITIS BASED ON THE STATUS OF POLYGLANDULAR POLYGLANDULAR AUTOIMMUNE SYNDROME
50. Mo1070 THE FIRSR EVIDENCE FOR SLFN11 EXPRESSION AS AN INDEPENDENT PROGNOSTIC FACTOR FOR PATIENTS WITH ESOPHAGEAL CANCER AFTER CHEMORADIOTHERAPY
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.